- Home
- IMNM vs SENS Comparison
IMNM vs SENS Comparison
Compare IMNM & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- SENS
- Stock Information
- Founded
- IMNM 2006
- SENS 1996
- Country
- IMNM United States
- SENS United States
- Employees
- IMNM N/A
- SENS N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- SENS Industrial Machinery/Components
- Sector
- IMNM Health Care
- SENS Industrials
- Exchange
- IMNM Nasdaq
- SENS Nasdaq
- Market Cap
- IMNM 1.2B
- SENS 360.5M
- IPO Year
- IMNM 2020
- SENS N/A
- Fundamental
- Price
- IMNM $16.07
- SENS $7.05
- Analyst Decision
- IMNM Strong Buy
- SENS Strong Buy
- Analyst Count
- IMNM 9
- SENS 6
- Target Price
- IMNM $24.89
- SENS $28.67
- AVG Volume (30 Days)
- IMNM 1.3M
- SENS 695.1K
- Earning Date
- IMNM 11-14-2025
- SENS 11-05-2025
- Dividend Yield
- IMNM N/A
- SENS N/A
- EPS Growth
- IMNM N/A
- SENS N/A
- EPS
- IMNM N/A
- SENS N/A
- Revenue
- IMNM $12,589,000.00
- SENS $25,466,000.00
- Revenue This Year
- IMNM N/A
- SENS $62.96
- Revenue Next Year
- IMNM $85.68
- SENS $72.62
- P/E Ratio
- IMNM N/A
- SENS N/A
- Revenue Growth
- IMNM 16.74
- SENS 5.94
- 52 Week Low
- IMNM $5.15
- SENS $5.00
- 52 Week High
- IMNM $17.32
- SENS $28.00
- Technical
- Relative Strength Index (RSI)
- IMNM 61.62
- SENS 75.64
- Support Level
- IMNM $15.44
- SENS $6.98
- Resistance Level
- IMNM $17.21
- SENS $7.56
- Average True Range (ATR)
- IMNM 1.13
- SENS 0.49
- MACD
- IMNM -0.15
- SENS 0.30
- Stochastic Oscillator
- IMNM 67.04
- SENS 79.82
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.